{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:09:21Z","timestamp":1781240961646,"version":"3.54.1"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T00:00:00Z","timestamp":1386547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0073159","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T21:18:01Z","timestamp":1386623881000},"page":"e73159","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Severe Upper Gastrointestinal Complications among Oral Bisphosphonate Users"],"prefix":"10.1371","volume":"8","author":[{"given":"Arianna","family":"Ghirardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Della Vedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cavalieri D'oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille P.","family":"Caputi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vaccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Gesuita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Vestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Staniscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Mazzaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BEST Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"ref2","first-page":"827","article-title":"Exercise interventions: defusing the world&apos;s osteoporosis time bomb","volume":"81","author":"MC Kai","year":"2003","journal-title":"Bull World Health Organ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"UA Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"DM Black","year":"1996","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"SR Cummings","year":"1998","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"HA Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"ST Harris","year":"1999","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"J Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"MR McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"ref10","first-page":"3109","article-title":"Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women","volume":"85","author":"RP Tonino","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"L Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"S Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1023\/A:1016495221567","article-title":"What the gastroenterologists should know about the gastrointestinal safety profiles of bisphosphonates","volume":"47","author":"DY Graham","year":"2002","journal-title":"Dig Dis Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"PC de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(97)00242-8","article-title":"Upper gastrointestinal adverse events and cyclical etidronate","volume":"103","author":"T Van Staa","year":"1997","journal-title":"Am J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.162.8.936","article-title":"Gastric and duodenal safety of daily alendronate","volume":"162","author":"JG Donahue","year":"2002","journal-title":"Arch Intern Med"},{"key":"ref17","first-page":"S207","article-title":"Incidence of gastrointestinal events among bisphosphonate patients in an observational setting","volume":"10","author":"RG Miller","year":"2004","journal-title":"Am J Manag Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-008-2278-2","article-title":"Bisphosphonate increases risk of gastroduodenal ulcer in rheumat7oiarthritis patients on long-term nonsteroidal antiinflammatory drug therapy","volume":"44","author":"K Miyake","year":"2009","journal-title":"J Gastroenterol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1365-2036.2009.03989.x","article-title":"Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study","volume":"29","author":"M Etminan","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00198-009-0871-8","article-title":"Comparative gastrointestinal safety of weekly oral bisphosphonates","volume":"20","author":"SM Cadarette","year":"2009","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"B Cryer","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"C MacLean","year":"2008","journal-title":"Ann Intern Med"},{"key":"ref23","unstructured":"Federal Information Processing Standards. Secure Hash Standard (SHS). PUB 180\u2013184;2000 (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/csrc.nist.gov\/publications\/drafts\/fips180-4\/Draft-FIPS180-4_Feb2011.pdf\" xlink:type=\"simple\">http:\/\/csrc.nist.gov\/publications\/drafts\/fips180-4\/Draft-FIPS180-4_Feb2011.pdf<\/ext-link>)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/aje\/kwn135","article-title":"Immeasurable time bias in observational studies of drug effects on mortality","volume":"168","author":"S Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.2053","article-title":"Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project","volume":"20","author":"PM Coloma","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"H Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"S Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial","volume":"160","author":"DC Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"H Taggart","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.PHM.0000122877.28631.23","article-title":"Beneficial effect of etidronate therapy in immobilized hip fracture patients","volume":"83","author":"Y Sato","year":"2004","journal-title":"Am J Phys Med Rehabil"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1359\/jbmr.2000.15.12.2487","article-title":"Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke","volume":"15","author":"Y Sato","year":"2000","journal-title":"J Bone Miner Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"CH Chesnut III","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"MR McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/01.STR.27.4.593","article-title":"Nimodipine neouroprotection in cardiac valve replacement","volume":"27","author":"C Legault","year":"1996","journal-title":"Stroke"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bmj.300.6720.278","article-title":"Non-steroidal anti-inflammatory drugs and peptic ulcers: facts and figures multiply, but do they add up?","volume":"300","author":"CJ Hawkey","year":"1990","journal-title":"Br Med J"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.1992.00400180139023","article-title":"The impact of research quality and study design on epidemiological estimates of the effects of NSAIDs on upper gastrointestinal pathology","volume":"152","author":"P Bollini","year":"1992","journal-title":"Arch Int Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non- steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"D Henry","year":"1996","journal-title":"Br Med J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archinte.158.1.33","article-title":"Risk of hospitalization for upper gastrointestinal bleeding associated with ketorolac, other NSAIDs, calcium antagonists and other antihypertensive drugs","volume":"158","author":"LA Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Arch Int Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archinte.163.1.59","article-title":"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study","volume":"163","author":"SO Dalton","year":"2003","journal-title":"Arch Int Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.162.8.936","article-title":"Gastric and duodenal safety of daily alendronate","volume":"162","author":"JG Donahue","year":"2002","journal-title":"Arch Int Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00002512-200724100-00003","article-title":"Bleeding peptic ulcer in the elderly: risk factors and prevention strategies","volume":"24","author":"A Zullo","year":"2007","journal-title":"Drugs Aging"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2036.2005.02543.x","article-title":"Does concurrent prescription of selective serotonin reuptake inhibitors and non- steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?","volume":"22","author":"LJ Tata","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","article-title":"Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s","volume":"160","author":"S Hern\u00e0ndez-Diaz","year":"2000","journal-title":"Arch Int Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00774-004-0538-7","article-title":"Multiple vertebral fractures are associated with refractary reflux esophagitis in postmenopausal women","volume":"23","author":"T Yamaguchi","year":"2005","journal-title":"J Bone Mineral Metab"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/gut.46.1.27","article-title":"Peptic ulcer bleeding: accessory risk factors and interactions with non- steroidal anti-inflammatory drugs","volume":"46","author":"J Weil","year":"2000","journal-title":"Gut"},{"key":"ref46","first-page":"1005","article-title":"Peptic ulcer disease","volume":"76","author":"K Ramakrishnan","year":"2007","journal-title":"Am Fam Physician"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/00365520701478758","article-title":"Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study","volume":"42","author":"M Udd","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/CIRCULATIONAHA.110.973008","article-title":"Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications","volume":"123","author":"LA Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"Circulation"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2009.07.020","article-title":"Fibrate\/Statin initiation in warfarin users and gastrointestinal bleeding risk","volume":"123","author":"H Schelleman","year":"2010","journal-title":"Am J Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00002018-200427060-00005","article-title":"Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents","volume":"27","author":"JR Laporte","year":"2004","journal-title":"Drug Saf"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Strom BL (2000) Overview of automated databases in pharmacoepidemiology. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed, New York: John Wiley &amp; Sons; pp. 219\u201322.","DOI":"10.1002\/0470842555"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-8278(02)00100-9","article-title":"Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation","volume":"37","author":"M Ninkovic","year":"2002","journal-title":"J Hepatol"},{"key":"ref53","first-page":"1595","article-title":"Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis","volume":"79","author":"IR Reid","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"EG Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"key":"ref55","first-page":"143","article-title":"Prevention of steroidinduced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)","volume":"1","author":"IR Reid","year":"1998","journal-title":"Lancet"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/PL00004179","article-title":"Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety","volume":"11","author":"PJ Ryan","year":"2000","journal-title":"Osteoporos Int"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01629581","article-title":"Role of oral pamidronate in preventing bone loss in postmenopausal women","volume":"6","author":"B Lees","year":"1996","journal-title":"Osteoporos Int"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension","volume":"17","author":"C Brumsen","year":"2002","journal-title":"J Bone Miner Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0895-4356(99)00004-9","article-title":"Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database","volume":"52","author":"C Cattaruzzi","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e10702","DOI":"10.1371\/journal.pone.0010702","article-title":"Statin treatment and mortality in bacterial infections. A systematic review and meta-analysis","volume":"5","author":"L Bj\u00f6rkhem-Bergman","year":"2010","journal-title":"Plos One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0073159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T18:32:17Z","timestamp":1564943537000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0073159"}},"subtitle":[],"editor":[{"given":"Alberico","family":"Catapano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,9]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0073159","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,9]]}}}